Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
28.28 USD
-1.67%
Market Closed
Updated:
May 4, 2024
Royalty Pharma PLC
Operating Income
|
Royalty Pharma PLC
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
Operating Income
$1.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Royalty Pharma PLC's Operating Income?
Operating Income
1.5B
USD
1.5B
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Operating Income amounts to 1.5B USD.
What is Royalty Pharma PLC's Operating Income growth rate?
Operating Income CAGR 5Y
2%
2%
Over the last year, the Operating Income growth was 62%. The average annual Operating Income growth rates for Royalty Pharma PLC have been -4% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
